CD44 and breast cancer: Yu, T. et al. (2020) [109] developed an HA-based nano-carrier loaded with doxorubicin (DOX) and cisplatin (CDDP) as a CD44–targeted drug delivery system and evaluated its tumor-suppressive effects on CD44+ breast cancer cells both in vitro and in vivo.